April 2019

Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, reacts to news of the London patient, the second person cured of HIV infection.

“A bite bug in the belly.”

New public health perspectives on aspergillosis, sporotrichosis, histoplasmosis, and coccidioidomycosis.

Warnings and concerns regarding fluoroquinolones are on the rise, but the antibiotics still play a role, albeit more limited, in the treatment of various infectious diseases.

A commentary on β-lactam combination therapy for methicillin-resistant Staphylococcus aureus bacteremia.

What can clinicians do now that increasing resistance has limited oral treatment options for outpatient cystitis?

What’s the 411 on 2-1-1?

The new single-tablet regimen provides a safe and effective treatment option for patients with HIV.

Are there advantageous effects to use of adjunctive IVIG in the treatment of STSS with clindamycin?

Incorporating clinical pharmacists and stewardship program oversights into PrEP models may improve the rate of retention in care.